These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2122652)

  • 41. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
    Factor SA
    Mov Disord; 1993 Apr; 8(2):240-1. PubMed ID: 8474504
    [No Abstract]   [Full Text] [Related]  

  • 43. Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
    Agnoli A; Stocchi F; Carta A; Antonini A; Bragoni M; Ruggieri SA
    Mt Sinai J Med; 1988 Jan; 55(1):62-6. PubMed ID: 3258057
    [No Abstract]   [Full Text] [Related]  

  • 44. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 45. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride.
    Mendis T; Mohr E; George A; Rusk IN; Gray P; Grimes JD
    Mov Disord; 1994 Mar; 9(2):197-200. PubMed ID: 8196683
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
    Busk K; Nyholm D
    Parkinsonism Relat Disord; 2012 Sep; 18(8):1000-1. PubMed ID: 22546333
    [No Abstract]   [Full Text] [Related]  

  • 49. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 50. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
    Obeso JA; Luquin MR; Martínez Lage JM
    Ann Neurol; 1986 Jan; 19(1):31-5. PubMed ID: 3947037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine and memory function in Parkinson's disease.
    Mohr E; Fabbrini G; Williams J; Schlegel J; Cox C; Fedio P; Chase TN
    Mov Disord; 1989; 4(2):113-20. PubMed ID: 2543918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG; Tanner CM; Gilley DW; Klawans HL
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parenteral administration of lisuride in Parkinson's disease.
    Luquin MR; Obeso JA; Martínez-Lage JM; Tresguerres J; Parada J; Nieuweboer B; Dorow R; Horowski R
    Adv Neurol; 1987; 45():561-8. PubMed ID: 3825733
    [No Abstract]   [Full Text] [Related]  

  • 56. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
    Nutt JG; Carter JH; Woodward W; Hammerstad JP; Gancher ST
    Mov Disord; 1993 Apr; 8(2):139-43. PubMed ID: 8474479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
    Kempster PA; Frankel JP; Bovingdon M; Webster R; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):718-23. PubMed ID: 2501456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.